Oncology Central

Once-weekly hypofractionated breast irradiation: fool’s gold or diamond in the rough?


Daily conventionally fractionated breast irradiation over 5–7 weeks is costly and inconvenient. Its use is associated with disparities in both the delivery of quality care and outcomes for vulnerable populations. Alternatively, daily hypofractionated breast irradiation delivered over 3 weeks exhibits equal efficacy and toxicity profiles. Today, a new generation of accelerated radiotherapy for breast cancer has emerged.

To view restricted content, please:



Leave A Comment